NuPathe raises $30,000,000

NuPathe Inc., a privately held specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, announced that the company has raised $30 million in a recently completed Series B equity financing.  NuPathe’s product portfolio includes NP101, which, if approved, will be the first and only transdermal patch for the treatment of acute migraine, and NP201, a long acting injectable implant for the treatment of Parkinson’s disease.